Search

Your search keyword '"Krämer, Alwin"' showing total 24 results
Start Over Author "Krämer, Alwin" Publisher wiley
24 results on '"Krämer, Alwin"'

2. Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia

Author

Kang, Dongwoo, primary, Ludwig, Elizabeth, additional, Jaworowicz, David, additional, Huang, Hannah, additional, Fiedler‐Kelly, Jill, additional, Cortes, Jorge, additional, Ganguly, Siddhartha, additional, Khaled, Samer, additional, Krämer, Alwin, additional, Levis, Mark, additional, Martinelli, Giovanni, additional, Perl, Alexander, additional, Russell, Nigel, additional, Abutarif, Malaz, additional, Choi, Youngsook, additional, Mendell, Jeanne, additional, and Yin, Ophelia, additional

Published
2020
Full Text
View/download PDF

3. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary

Author

Bochtler, Tilmann, primary, Reiling, Anna, additional, Endris, Volker, additional, Hielscher, Thomas, additional, Volckmar, Anna‐Lena, additional, Neumann, Olaf, additional, Kirchner, Martina, additional, Budczies, Jan, additional, Heukamp, Lukas C., additional, Leichsenring, Jonas, additional, Allgäuer, Michael, additional, Kazdal, Daniel, additional, Löffler, Harald, additional, Weichert, Wilko, additional, Schirmacher, Peter, additional, Stenzinger, Albrecht, additional, and Krämer, Alwin, additional

Published
2020
Full Text
View/download PDF

4. Micronucleus formation in human cancer cells is biased by chromosome size

Author

Bochtler, Tilmann, Kartal-Kaess, Mutlu, Granzow, Martin, Hielscher, Thomas, Cosenza, Marco R, Herold-Mende, Christel, Jauch, Anna, and Krämer, Alwin

Subjects
610 Medicine & health
Abstract

Chromosomal instability is one of the hallmarks of cancer and caused by chromosome missegregation during mitosis, a process frequently associated with micronucleus formation. Micronuclei are formed when chromosomes fail to join a daughter nucleus during cell division and are surrounded by their own nuclear membrane. Although it has been commonly assumed that the gain or loss of specific chromosomes is random during compromised cell division, recent data suggest that the size of chromosomes can impact on chromosome segregation fidelity. To test whether chromosome missegregation rates scale with chromosome size in primary human cancer cells, we assessed chromosome sequestration into micronuclei in patient-derived primary NCH149 glioblastoma cells, which display high-level numerical chromosome instability (CIN), pronounced spontaneous micronucleus formation but virtually no structural CIN. The cells were analysed by interphase fluorescence-in-situ-hybridization (FISH) using chromosome-specific painting probes for all chromosomes. Overall, 33% of early passage NCH149 cells harbored micronuclei. Entrapment within a micronucleus clearly correlated with chromosome size with larger chromosomes being significantly more frequently missegregated into micronuclei than smaller chromosomes in primary glioblastoma cells. These findings extend the concept that chromosome size determines segregation fidelity by implying that size-specific micronucleus entrapment occurs in primary human cancer cells as well. This article is protected by copyright. All rights reserved.

Published
2019
Full Text
View/download PDF

5. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome

Author

Bochtler, Tilmann, primary, Endris, Volker, additional, Leichsenring, Jonas, additional, Reiling, Anna, additional, Neumann, Olaf, additional, Volckmar, Anna‐Lena, additional, Kirchner, Martina, additional, Allgäuer, Michael, additional, Schirmacher, Peter, additional, Krämer, Alwin, additional, and Stenzinger, Albrecht, additional

Published
2019
Full Text
View/download PDF

7. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

Author

Döhner, Hartmut, primary, Müller‐Tidow, Carsten, additional, Lübbert, Michael, additional, Fiedler, Walter, additional, Krämer, Alwin, additional, Westermann, Jörg, additional, Bug, Gesine, additional, Schlenk, Richard F., additional, Krug, Utz, additional, Goeldner, Rainer‐Georg, additional, Hilbert, James, additional, Taube, Tillmann, additional, and Ottmann, Oliver G., additional

Published
2018
Full Text
View/download PDF

8. CD7 is expressed on a subset of normal CD34-positive myeloid precursors

Author

Kriegsmann, Katharina, primary, Löffler, Harald, additional, Eckstein, Volker, additional, Schulz, Renate, additional, Kräker, Sandra, additional, Braun, Ute, additional, Luft, Thomas, additional, Hegenbart, Ute, additional, Schönland, Stefan, additional, Dreger, Peter, additional, Krämer, Alwin, additional, Ho, Anthony D., additional, Müller-Tidow, Carsten, additional, and Hundemer, Michael, additional

Published
2018
Full Text
View/download PDF

9. Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

Author

Ottmann, Oliver G., primary, Müller‐Tidow, Carsten, additional, Krämer, Alwin, additional, Schlenk, Richard F., additional, Lübbert, Michael, additional, Bug, Gesine, additional, Krug, Utz, additional, Bochtler, Tilmann, additional, Voss, Florian, additional, Taube, Tillmann, additional, Liu, Dan, additional, Garin‐Chesa, Pilar, additional, and Döhner, Hartmut, additional

Published
2018
Full Text
View/download PDF

10. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients

Author

Kayser, Sabine, primary, Feszler, Maximilian, additional, Krzykalla, Julia, additional, Schick, Matthias, additional, Kramer, Michael, additional, Benner, Axel, additional, Thol, Felicitas, additional, Platzbecker, Uwe, additional, Müller‐Tidow, Carsten, additional, Ho, Anthony D., additional, Ehninger, Gerhard, additional, Heuser, Michael, additional, Schlenk, Richard F., additional, Thiede, Christian, additional, Röllig, Christoph, additional, and Krämer, Alwin, additional

Published
2017
Full Text
View/download PDF

11. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

Author

Witzens-Harig, Mathias, primary, Benner, Axel, additional, McClanahan, Fabienne, additional, Klemmer, Jennifer, additional, Brandt, Julia, additional, Brants, Elke, additional, Rieger, Michael, additional, Meissner, Julia, additional, Hensel, Manfred, additional, Neben, Kai, additional, Dreger, Peter, additional, Lengfelder, Eva, additional, Schmidt-Wolf, Ingo, additional, Krämer, Alwin, additional, and Ho, Anthony D., additional

Published
2015
Full Text
View/download PDF

12. Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort

Author

Kaaks, Rudolf, primary, Sookthai, Disorn, additional, Hemminki, Kari, additional, Krämer, Alwin, additional, Boeing, Heiner, additional, Wirfält, Elisabet, additional, Weiderpass, Elisabete, additional, Overvad, Kim, additional, Tjønneland, Anne, additional, Olsen, Anja, additional, Peeters, Petra H., additional, Bueno‐de‐Mesquita, H. B(as), additional, Panico, Salvatore, additional, Pala, Valeria, additional, Vineis, Paolo, additional, Quirós, J. Ramón, additional, Ardanaz, Eva, additional, Sánchez, María‐José, additional, Chirlaque, Maria‐Dolores, additional, Larrañaga, Nerea, additional, Brennan, Paul, additional, Trichopoulos, Dimitrios, additional, Trichopoulou, Antonia, additional, Lagiou, Pagona, additional, Hallmans, Göran, additional, Khaw, Kay‐Tee, additional, Key, Timothy J., additional, Riboli, Elio, additional, and Canzian, Federico, additional

Published
2014
Full Text
View/download PDF

14. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia

Author

Müller-Tidow, Carsten, primary, Bug, Gesine, additional, Lübbert, Michael, additional, Krämer, Alwin, additional, Krauter, Jürgen, additional, Valent, Peter, additional, Nachbaur, David, additional, Berdel, Wolfgang E., additional, Ottmann, Oliver G., additional, Fritsch, Holger, additional, Munzert, Gerd, additional, Garin-Chesa, Pilar, additional, Fleischer, Frank, additional, Taube, Tillmann, additional, and Döhner, Hartmut, additional

Published
2013
Full Text
View/download PDF

19. Expression of centrosome‐associated gene products is linked to tetraploidization in mantle cell lymphoma

Author

Neben, Kai, primary, Ott, German, additional, Schweizer, Silja, additional, Kalla, Jörg, additional, Tews, Björn, additional, Katzenberger, Tiemo, additional, Hahn, Meinhard, additional, Rosenwald, Andreas, additional, Ho, Anthony D., additional, Müller‐Hermelink, Hans Konrad, additional, Lichter, Peter, additional, and Krämer, Alwin, additional

Published
2007
Full Text
View/download PDF

24. Palbociclib in Acute Leukemias With KMT2A -rearrangement: Results of AMLSG 23-14 Trial.

Author

Gaidzik VI, Paschka P, Schlenk RF, Weber D, Fröhling S, Krämer A, Wäsch R, Westermann J, Mayer K, de Wit M, Fiedler W, Benner A, Heuser M, Thol F, Döhner K, Ganser A, and Döhner H

Abstract

Competing Interests: VIG: Consulting or advisory board membership: Jazz Pharmaceuticals; Speakers bureau: Abbvie, Janssen, Pfizer; Travel or accommodation expenses: AbbVie. PP: Consulting or advisory board membership: AbbVie, Agios, Astellas, Astex, Bristol-Meyers Squibb, Celgene, Jazz, Novartis, Otsuka, Pfizer, Sunesis; Speakers bureau: AbbVie, Agios, Astellas, Bristol-Meyers Squibb, Celgene, Jazz, Novartis, Pfizer; Travel or accommodation expenses: AbbVie, Amgen, Bristol-Meyers Squibb, Celgene, Janssen, Novartis, Takeda. RFS: Consulting or advisory board membership: Abbvie, Agios, Astellas, Celgene, Daiichi Sankyo, Hexal, Neovio Biotech, Novartis, Pfizer, Roche; research funding: Astellas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Roche; speakers bureau, Astellas, Pfizer. SF: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche. AK: Consulting, honoraria, advisory board membership: Roche; research funding: BMS, Roche. RW: Consulting or advisory board: Janssen, Novartis, BMS/Celgene, Amgen, Gilead, Pfizer, Sanofi, Takeda; research funding: Janssen, Sanofi; Honoraria: Abbvie, Sanofi, Takeda, Janssen, Amgen, BMS/Celgene, Gilead, Pfizer. JW: Consulting or advisory board membership: Novartis, Bristol Myers Squibb, Celgene, Amgen, Abbvie, Agios, Jazz, Pfizer, Sanofi, Sobi, Astellas. MdW: Research funding: Pfizer, Abbvie, Novartis, Astellas, Bristol Myers Squibb, AstraZeneca, MorphoSys; speakers honoraria: AstraZeneca, Janssen; travel or accommodation expenses: Astellas, Janssen. WF: Consulting or advisory board membership: AbbVie, Amgen, Celgene, Jazz Pharmaceuticals, MorphoSys AG, Novartis, Pfizer; Stemline and Clinigen; research funding: from Amgen and Pfizer; patents and royalties: Amgen; travel or accommodation expenses: Amgen, Daiichi Sankyo, Gilead, Jazz Pharmaceuticals, and Servier. MH: Consulting or advisory board: Abbvie, BMS/Celgene, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, Roche, Tolremo. Honoraria: Jazz Pharmaceuticals, Janssen, Novartis; research funding: Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Jazz Pharmaceuticals, Karyopharm, Novartis, Pfizer, Roche. FT: Consulting or advisory board: Abbvie, Astellas, Bristol Myers Squibb/Celgene, Jazz Pharmaceuticals, Novartis, Pfizer. KD: Consulting or advisory board: Novartis, Celgene/BMS, Abbvie, Jazz Pharmaceuticals; research funding: Novartis; Celgene/BMS, Astellas, Agios, Kronos; Honoraria: Novartis, Celgene/BMS, Jazz Pharmaceuticals. HD: Consulting or advisory board: AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, Daiichi Sankyo, Gilead, Janssen, Jazz, Novartis, Servier, Syndax; Clinical Research Funding to Institution: AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Novartis, Pfizer. All the other authors have no conflicts of interest to disclose.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results